Topics

Myeloma Canada Company Profile

07:27 EST 16th December 2019 | BioPortfolio

Multiple myeloma, a cancer of the bone marrow, is an incurable but treatable disease. The cancer starts in plasma cells, which are produced in the bone marrow. In myeloma, abnormal plasma cells, called myeloma cells, grow uncontrollably, crowding out the normal blood cells in the bone. This can bring on symptoms such as fatigue, recurrent infections and severe pain resulting from bone fractures. The disease disturbs the body's balance of minerals and prevents organs, such as the kidney, as well as nerves, from functioning properly. In Canada, approximately 2,300 people are diagnosed with multiple myeloma every year and 1,350 patients die from the disease annually.


News Articles [897 Associated News Articles listed on BioPortfolio]

Myeloma UK launches new research program to support patient-centric myeloma clinical trials

Myeloma UK is launching a new research program to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Progra...

Revlimid Decreases Risk of Progression to Myeloma in Smoldering Myeloma

Revlimid can delay progression of smoldering myeloma to multiple myeloma but not without side effects.

Quadruplet Regimens Show Promising Activity in Multiple Myeloma

Ajai Chari, MD, discusses current and emerging research in patients with transplant-eligible and -ineligible multiple myeloma as well as updates in smoldering multiple myeloma.

Intriguing BCMA-Targeted Therapies Move Through Myeloma Pipeline

Investigators are exploring various treatment modalities in the multiple myeloma pipeline, many of them using BCMA as a target because of its high expression on myeloma cells.

Neurological concerns in multiple myeloma

Prof Wolfgang Grisold speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the relationship between neuropathy and multiple myeloma. He describes a case study, in which the appearanc...

Myeloma bone disease: Clinical features and complications

Dr Andrew Chantry speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about bone disease in multiple myeloma. He describes the pathophysiology of this disease and the current treatments a...

Under the lens: Laboratory techniques for the diagnosis of multiple myeloma

Dr Bruno Paiva speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the diagnostic techniques that should be performed to diagnose and monitor multiple myeloma. He mentions the curre...

Diagnosis and detection of smouldering multiple myeloma

Dr Elena Zamagni speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the diagnostic techniques available in smouldering multiple myeloma. She emphasises the importance of using nove...

PubMed Articles [635 Associated PubMed Articles listed on BioPortfolio]

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitar...

Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry.

We describe survival in patients with oligo-and non-secretory multiple myeloma (MM). We refer to the whole group as non-measurable MM and compare it with secretory MM.

Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.

All patients who develop multiple myeloma have a preceding asymptomatic expansion of clonal plasma cells, clinically recognized as monoclonal gammopathy of undetermined significance or smoldering mult...

Source Contributions to Ambient Fine Particulate Matter for Canada.

Understanding the sectoral contribution of emissions to fine particulate matter (PM2.5) offers information for air quality management, and for investigation of association with health outcomes. This s...

Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities.

Outcomes in multiple myeloma (MM) have improved significantly over time. This is true overall for all patients as well as patient subgroups based on age and race/ethnicity. Despite this, disparities a...

Clinical Trials [1936 Associated Clinical Trials listed on BioPortfolio]

Multiple Myeloma Molecular Monitoring Study

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment....

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and...

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be effective in preventing multiple myelo...

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

This research is being done to find out if the investigators can improve outcomes for multiple myeloma patients by giving a myeloma vaccine to patients who are already on lenalidomide (Rev...

Companies [877 Associated Companies listed on BioPortfolio]

Myeloma Canada

Multiple myeloma, a cancer of the bone marrow, is an incurable but treatable disease. The cancer starts in plasma cells, which are produced in the bone marrow. In myeloma, abnorma...

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

The Multiple Myeloma Research Consortium (MMRC)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2011, mo...

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, ap...

Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...

More Information about "Myeloma Canada" on BioPortfolio

We have published hundreds of Myeloma Canada news stories on BioPortfolio along with dozens of Myeloma Canada Clinical Trials and PubMed Articles about Myeloma Canada for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Myeloma Canada Companies in our database. You can also find out about relevant Myeloma Canada Drugs and Medications on this site too.

Quick Search

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...


Corporate Database Quicklinks



Searches Linking to this Company Record